These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10729746)

  • 1. Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis.
    Luca ME; Paul LC; van Der Wal AM; Bruijn JA; de Heer E
    Exp Nephrol; 2000; 8(2):77-83. PubMed ID: 10729746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis.
    Makker SP
    J Immunol; 1993 Dec; 151(11):6500-8. PubMed ID: 8245481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition.
    Penny MJ; Boyd RA; Hall BM
    J Am Soc Nephrol; 1998 Dec; 9(12):2272-82. PubMed ID: 9848781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Heymann nephritis with a gp330/megalin fusion protein.
    Raychowdhury R; Zheng G; Brown D; McCluskey RT
    Am J Pathol; 1996 May; 148(5):1613-23. PubMed ID: 8623929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats.
    Kerjaschki D; Farquhar MG
    J Exp Med; 1983 Feb; 157(2):667-86. PubMed ID: 6337231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-induced redistribution of Heymann antigen on the surface of cultured glomerular visceral epithelial cells: possible role in the pathogenesis of Heymann glomerulonephritis.
    Camussi G; Brentjens JR; Noble B; Kerjaschki D; Malavasi F; Roholt OA; Farquhar MG; Andres G
    J Immunol; 1985 Oct; 135(4):2409-16. PubMed ID: 3875653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis.
    Susani M; Schulze M; Exner M; Kerjaschki D
    Am J Pathol; 1994 Apr; 144(4):807-19. PubMed ID: 8160779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccination against specific pathogenic TCRs reduces proteinuria in active Heymann nephritis by inducing specific autoantibodies.
    Wu H; Walters G; Knight JF; Alexander SI
    J Immunol; 2003 Nov; 171(9):4824-9. PubMed ID: 14568961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic fate of monovalent and multivalent antibodies of Heymann nephritis following formation of surface immune complexes on glomerular epithelial cells.
    Singh AK; Kasinath BS
    Clin Exp Immunol; 1993 Dec; 94(3):403-11. PubMed ID: 8252800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small N-terminal 60-kD fragment of gp600 (megalin), the major autoantigen of active Heymann nephritis, can induce a full-blown disease.
    Oleinikov AV; Feliz BJ; Makker SP
    J Am Soc Nephrol; 2000 Jan; 11(1):57-64. PubMed ID: 10616840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope specificity of anti-gp330 autoantibodies determines the development of proteinuria in active Heymann nephritis.
    Van Leer EH; Ronco P; Verroust P; van der Wal AM; Hoedemaeker PJ; De Heer E
    Am J Pathol; 1993 Mar; 142(3):821-9. PubMed ID: 7681258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive Heymann nephritis with acute and severe proteinuria induced by heterologous antibody against renal tubular brush border glycoprotein gp108.
    Natori Y; Hayakawa I; Shibata S
    Lab Invest; 1986 Jul; 55(1):63-70. PubMed ID: 3755192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
    Avasare RS; Canetta PA; Bomback AS; Marasa M; Caliskan Y; Ozluk Y; Li Y; Gharavi AG; Appel GB
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):406-413. PubMed ID: 29326307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of terminal complement complex in active Heymann nephritis.
    de Heer E; Daha MR; Bhakdi S; Bazin H; van Es LA
    Kidney Int; 1985 Feb; 27(2):388-93. PubMed ID: 3886996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis.
    Nieto E; Escudero E; Navarro E; Yáñez-Mo M; Martín A; Pérez de Lema G; Sánchez-Madrid F; Mampaso F
    J Am Soc Nephrol; 2002 Apr; 13(4):937-945. PubMed ID: 11912253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis.
    Nakazawa M; Emancipator SN; Lamm ME
    J Exp Med; 1986 Dec; 164(6):1973-87. PubMed ID: 3537193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe glomerular epithelial cell damage does not prevent passive Heyman nephritis in rats.
    Bertani T; Remuzzi G; Poggi A; Delaini F; Sacchi G; Morassi L; Verroust P; Mecca G; Donati MB
    Clin Exp Immunol; 1983 Jan; 51(1):38-44. PubMed ID: 6339125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil prevents development of urinary protein in autoimmune nephritis.
    Takeda S; Takahashi M; Kusano E; Kobayashi E
    Kidney Int; 2003 Jul; 64(1):365-6; author reply 366. PubMed ID: 12787433
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis.
    Lotan D; Kaplan BS; Fong JS; Goodyer PR; de Chadarevian JP
    Kidney Int; 1984 May; 25(5):778-88. PubMed ID: 6471664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis.
    Makker SP; Tramontano A
    J Pathol; 2006 Nov; 210(3):282-7. PubMed ID: 16981232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.